SMARCA4-deficient thoracic sarcoma revealed by metastasis to the small intestine: a diagnostic dilemma

Fatma Khanchel1,2 · Raweh Hedhili1,2 · Hakim Zenaidi1,3 · Imen Helal1,2 · Abdelwahed Yahmadi1,3 · Hend Ben Néji4 · Feryel Ksontini1,5 · Ehsen Ben Brahim1,2 · Raja Jouini1,2 · Aschraf Chadli1,2

Received: 6 August 2020 / Accepted: 23 March 2021 / Published online: 17 April 2021
© The Author(s) 2021

Abstract
SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a recently identified aggressive subtype of sarcoma. We present the case of a 44-year-old man who underwent a surgery for a perforated small intestine. Computed tomography scan revealed a tumoral mediastino–pulmonary mass. Histopathological examination of the intestinal mass showed a malignant tumour with a typical epithelioid and rhabdoid cells, numerous mitoses and large necrosis. A large panel of immunohistochemistry revealed loss of SMARCA4 and SMARCA2 and allowed the diagnosis of SMARCA4-DTS. It is important to consider SMARCA4-deficient thoracic sarcoma in the differential diagnosis of tumours showing suggestive morphologic features in patients of all ages, especially in the case of metastasis associated with thoracic mass.

Introduction
SMARCA4-deficient thoracic sarcoma (SMARCA4-DTS) is a distinct subset of intrathoracic tumors, recognised for the first time in 2015 by Le Loarer et al. [1]. This tumor is characterized by inactivating mutations of SMARC4, a gene encoding the ATPase subunit of the switch/sucrose non-fermenting (SWI/SNF) chromatin remodelling complexes. It has an extremely poor prognosis with metastatic disease at the time of presentation and a median survival of 6–7 months [2]. Recognizing SMARCA4-DTS from other malignant epithelioid tumors is clinically relevant.

We report a case of a SMARCA4-DTS revealed by intestinal metastasis with an emphasis on differential diagnosis.

Case report
A previously healthy 44-year-old man, with a 25-pack-year smoking history, underwent a surgery for acute peritonitis revealing a perforated small intestine mass with numerous peritoneal nodules and large lymph nodes.

We received a 26-cm-long segment of the small intestine measuring two lymph nodes and a peritoneal nodule. The intestine includes an ulcerating and infiltrating tumor of 6 cm. Several samples were taken. Histological examination showed a malignant tumor with poorly cohesive sheets of large cells with an epithelioid and rhabdoid appearance (Fig. 1a). The tumor cells were anisocaryotic without major pleomorphism. Their cytoplasm was globoid and eosinophilic and the irregularly shaped nuclei had vesicular chromatin with large nucleoli (Fig. 1b). Mitoses and areas of geographic necrosis were numerous. Lymph nodes and the peritoneal nodule were massively infiltrated by this tumor. The immunohistochemical study showed a diffuse tumour cell positivity with vimentin, CD34, and SOX2 with more heterogeneous positivity for SALL4 (Fig. 1c, d). It revealed negative expression to epithelial markers CK AE1/AE3, Pan-CK and EMA ruling out the diagnosis of an undifferentiated carcinoma (Fig. 1e). Large cell lymphoma was also excluded by negative expression of lymphoid markers (CD45, CD20, PAX5, CD79a, MUM1, CD138, CD163, CD43, CD3, CD5, CD7, CD68, CD163, TdT, MPO, CD30, CD163, TdT, MPO, CD30).
CD15, ALK, XCL13, CD21, CD23) (Fig. 1f). Epithelioid sarcoma showing strong and diffuse positivity to EMA and Vimentin was also excluded. In the same way, malignant peripheral nerve sheath tumour and melanoma were ruled out by negative expression of S-100. Also tumour cells did not express neither CD117 nor DOG-1 making the diagnosis of gastro-intestinal stromal tumor unlikely. Negativity to CDK4 and MDM2 eliminated the diagnosis of liposarcoma. Negativity to CD31 and Desmin excluded, respectively, a vascular and a muscular differentiation of this tumor. In the same way negativity to synaptophysin, chromogranin and CD56 ruled out a neuroendocrine differentiation. The proliferation index was estimated at 60% and the PDL1 was <1%. After this large panel of immunohistochemistry the diagnosis remained doubtful. A computed tomography scan, performed after the intervention, revealed a tissular mediastino–pulmonary mass measuring 47 × 100 × 116 mm encompassing left pulmonary arteries, left common carotid and aortic arch and repressing superior vena cava (Fig. 2). This mass was inseparable from latero-tracheal enlarged lymph nodes. In the abdomen, there was an 80 × 70 × 64 mm tumour residue, large lymph nodes, and bilateral adrenal masses.

Based on computed tomography scan data a complementary immunohistochemical investigations were performed and they revealed that tumor cells exhibited a loss of expression of both SMARCA4 and SMARCA2 while SMARCB1 was retained (Fig. 3a, b).
Thus morphology and immunophenotype, coupled with the computed tomography data and clinical history, were consistent with the diagnosis of SMARCA4-deficient thoracic sarcoma to the small bowel.

The patient received two cycles of chemotherapy with gemcitabine and cisplatin. He died 6 months after the diagnosis from a digestive haemorrhage.

Discussion

SMARCA4-DTS is first described in 2015 by Le Loarer et al. [1]. The authors compared transcriptomic profiles of unclassified thoracic sarcomas showing SMARCA4 inactivation with those of SMARCA4-mutated small-cell carcinomas of the ovary, hypercalcemic type (SCCOHTs), SMARCB1-inactivated malignant rhabdoid tumors (MRTs), and lung carcinomas (of which 5–10% has SMARCA4 mutations) [1]. As a result, SMARCA4-DTSs were found to be genetically different from lung carcinomas while they displayed a closer molecular relationship to SCCOHT and MRTs [1].

The SMARCA4 gene, located on chromosome 19p13, encodes the BRG1 protein. The SMARCA2 gene, located on chromosome 9p24 encodes the BRM protein. These two proteins are mutually exclusive catalytic subunits of the SWI/SNF chromatin-remodelling complex which is formed by multiple other proteins, among which INI-1 (encoded by SMARCB1 gene). By regulating transcription, promoting cell differentiation, and repairing the DNA, the complex acts as a tumour suppressor [3]. Studies have demonstrated that up to 20% of human malignancies contain a mutation of one of the subunits of the SWI/SNF complex and span many tumors types [4].

Usually, clinical presentation of SMARCA4-DTS is a compressive and infiltrative large mediastinal mass, rarely found in the lung [2]. They occur in middle-aged males with a heavy smoking history [1]. Most of the cases present with metastatic disease involving lymph node, bone, adrenal glands, skin [2, 5–7]. In addition, these tumours have a predilection for bulky peritoneal metastases, which may raise a consideration for an abdominal primary like in the case of our patient [2]. Hence, to have a correct diagnosis, thorax radiological features are very helpful.

In typical cases, SMARCA4-DTSs is a poorly differentiated neoplasm of round to epithelioid cells with prominent cytological atypia organized in a solid pattern and showing rhabdoid differentiation [1]. Mitosis and necrosis are common [1]. Immunohistochemical analysis of SMARCA4 and SMARCA2 expressions, respectively based on BRG1 and BRM immunohistochemistry, shows a dual loss [1]. Expression of SOX2 is often diffuse and in most cases epithelial markers (CK AE1-AE3 or EMA), CD34, and/or SALL4 are focally expressed [1]. Other markers are generally requested to rule out differential diagnoses. In our case, undiffernciated carcinoma is a differential diagnosis but it is immunopositive for epithelial markers CK AE1/AE3, Pan-CK and EMA. Large cell lymphoma is also a differential diagnosis but was ruled out by negative expression of lymphoid markers. Epithelioid sarcoma shows a strong and diffuse positivity to EMA and vimentin. Malignant peripheral nerve sheath tumour and melanoma were also ruled out by negative S-100 immunohistochemistry. The dual loss of SMARCA4 and SMARCA2, the diffuse positivity for CD34.
and SOX2, the heterogeneous positivity for SALL4, in addition to thorax radiological features confirmed the diagnosis of a SMARCA4-DTS.

In 2019, Perret and Le Loarer’s group in France proposed three criteria, deemed sufficiently significant in terms of specificity and sensitivity, based on which the diagnosis of SMARCA4-DTS intrathoracic malignancies ought to be carried: (1) rhabdoid or poorly differentiated phenotype, (2) complete loss of expression of SMARCA4 and SMARCA2, and (3) focal or diffuse expression of at least two of the following markers: SOX2, CD34, or SALL4 [8]. But the diagnosis is particularly difficult in the case of inaugural metastases, which is similar to our case. The main differential diagnosis of SMARCA4-DT in the intestinal tract are epithelioid gastro-intestinal stromal tumor, melanoma, undifferentiated carcinoma, and epithelioid malignant nerve sheath tumor. Even though the immunophenotype of SMARCA4-DTS is quite specific, appropriate clinicopathologic correlation should be performed in all cases to avoid misclassification [8].

The prognosis for SMARCA4-DTS cases is poor because treatment strategies for these tumors have not been established. The estimated median overall survival duration is 7 months [2]. Presently, specific therapies combining the enhancer of zeste homolog (EZH2) inhibitors, used in patients with abnormalities in the SWI/SNF complex protein, and the topoisomerase II inhibitor are widely supported [4]. The estimated median overall survival duration is 7 months [2].

Acknowledgements Dr Marie Parrens Pathology Department, Haut Lévéque Hospital, University Hospital Centre of Bordeaux, Pessac, France. Dr François Le Loarer, Department of Pathology, Institut Bergonié, 276 cours de l’Argonne, 33000, Bordeaux, France; University of Bordeaux, Talence, France. Dr Houda Ben Rejeb, Institut Bergonié, 276 cours de l’Argonne, 33000, Bordeaux, France; University of Bordeaux, Talence, France

Declarations

Conflict of interest Fatma Khanchel has non conflict of interest, Hedhil Raoueh has non conflict of interest, Zenaïd Hakim has non conflict of interest, Imen Helal has non conflict of interest, Yahmadi Abdelwahed has non conflict of interest, Hend Ben Neji has non conflict of interest, Feryel Ksontini has non conflict of interest, Ehsen Ben Brahim has non conflict of interest, Raja Jouini has non conflict of interest, Aschraf Chadli has non conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, et al. SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nat Genet. 2015;47:1200–5. https://doi.org/10.1038/ng.3399.
2. Yoshida A, Kobayashi E, Kubo T, Kodaira M, Motoi T, Motoi N, et al. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol. 2017;30:797–809. https://doi.org/10.1038/modpathol.2017.11.
3. Roberts CWM, Orkin SH. The SWI/SNF complex—chromatin and cancer. Nat Rev Cancer. 2004;4:133–42. https://doi.org/10.1038/nrc1273.
4. Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45:592–601. https://doi.org/10.1038/ng.2628.
5. Leckey Cutaneous metastasis of SMARCA4-deficient thoracic sarcoma: a diagnostic dilemma with therapeutic implications. Journal of cutaneous pathology. Wiley Online Library. https://onlinelibrary.wiley.com/doi/abs/https://doi.org/10.1111/cup.13652. Accessed 11 May 2020
6. Kunimas K, Nakamura H, Sakai K, Tamiya M, Kimura M, Inoue T, et al. Patients with SMARCA4-deficient thoracic sarcoma and severe skeletal-related events. Lung Cancer. 2019;132:59–64. https://doi.org/10.1016/j.lungcan.2019.03.029.
7. Sauter JL, Graham RP, Larsen BT, Jenkins SM, Roden AC, Boland JM. SMARCA4-deficient thoracic sarcoma: a distinctive clinicopathological entity with undifferentiated rhabdoid morphology and aggressive behavior. Mod Pathol. 2017;30:1422–32. https://doi.org/10.1038/modpathol.2017.61.
8. Perret R, Chalabreysse L, Watson S, Serre I, Garcia S, Forest F, et al. SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with an emphasis on their nosology and differential diagnoses. Am J Surg Pathol. 2019;43:455–65. https://doi.org/10.1097/PAS.0000000000001188.
9. Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, et al. SMARCA4-deficient thoracic sarcomatoid tumors represent primarily smoking-related undifferentiated carcinomas rather than primary thoracic sarcomas. J Thorac Oncol. 2020;15:231–47. https://doi.org/10.1016/j.jtho.2019.10.023.
10. Takeda M, Tani Y, Saijo N, Shimizu S, Taniguchi Y, Otsuka K, et al. Cytopathological features of SMARCA4-deficient thoracic sarcoma: report of 2 cases and review of the literature. Int J Surg Pathol. 2020;28:109–14. https://doi.org/10.1177/1066896919870866.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.